 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on May 22, 2024 |
| Title |
Synergically enhanced anti-tumor immunity of in vivo CAR by vaccination-elicited antibody-mediated cellular cytotoxicity boosting |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Chimeric Antigen Receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies. However, it is limited to individualized cell therapy and faces challenges, including high costs, extended preparation time, and limited efficacy against solid tumors. Here, we generated circular RNAs (circRNAs) encoding Chimeric Antigen Receptor (CAR) transmembrane proteins, referred to as circRNACAR, which mediated remarkable tumor killing in both T cells and macrophages. In addition, macrophages exhibited efficient phagocytosis of tumor cells and pro-inflammatory polarization induced by circRNACAR in vitro. We demonstrated that circRNACAR, delivered with immunocyte-tropic lipid nanoparticles (LNPs), significantly inhibited tumor growth, improved survival rates and induced a pro-inflammatory tumor microenvironment in mice. Importantly, the combination of circRNAAnti-HER2-CAR and circRNA-based cancer vaccines encoding the corresponding transmembrane HER2 antigen, termed circRNAHER2, exhibited synergistically enhanced anti-tumor activity. Notably, we found that circRNACAR could boost the level of circRNAHER2-elicited antibodies, which could mediate effective killing of HER2+ tumor cells by macrophages, indicating the potential of vaccination-elicited antibodies in developing novel immunotherapy. This proof-of-concept study demonstrated that the combination of circRNA-based in vivo CAR and vaccines, termed in vivo CAR-VAC, holds the potential to become an upgraded off-the-shelf immunotherapy, and also sheds light on the huge potential of vaccination-elicited antibodies in cancer immunotherapy.
|
| |
|
| Overall design |
comparative gene expression profiling analysis of RNA-seq data for tumor-infiltrating immune cells after PBS, circRNAEV or circRNACAR treatment.
|
| |
|
| Contributor(s) |
Wang Y, Wang X, Zhao C, Xu Y, Qu L |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
May 22, 2024 |
| Last update date |
May 22, 2024 |
| Contact name |
Chengzhi Zhao |
| E-mail(s) |
12233041@mail.sustech.edu.cn
|
| Organization name |
Southern University of Science and Technology
|
| Street address |
Xue Yuan Avenue 1088, Nanshan District, Shenzhen, China
|
| City |
Shenzhen |
| ZIP/Postal code |
518055 |
| Country |
China |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (6)
|
| GSM8285879 |
Tumor-infiltrating immune cells, PBS control 1 |
| GSM8285880 |
Tumor-infiltrating immune cells, PBS control 2 |
| GSM8285881 |
Tumor-infiltrating immune cells, LNP-circRNAEV 1 |
| GSM8285882 |
Tumor-infiltrating immune cells, LNP-circRNAEV 2 |
| GSM8285883 |
Tumor-infiltrating immune cells, LNP-circRNACAR 1 |
| GSM8285884 |
Tumor-infiltrating immune cells, LNP-circRNACAR 2 |
|
| Relations |
| BioProject |
PRJNA1114686 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE268105_gene_Count.txt.gz |
479.5 Kb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
|
|
|
|
 |
Less...
More...